Arca biopharma, inc. (ABIO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13Sep'12Jun'12Sep'11Jun'11Jun'10
Costs and expenses:
Research and development

1,536

1,833

2,074

2,467

3,181

4,239

6,448

9,196

12,550

14,076

14,363

14,595

13,000

12,348

11,120

9,116

7,950

7,063

6,752

6,371

6,024

5,625

4,757

3,668

0

0

0

0

0

0

0

0

General and administrative

3,837

3,981

3,989

4,011

3,945

3,879

4,440

4,505

4,554

4,636

4,344

4,349

4,326

4,265

4,376

4,485

4,429

4,392

4,140

3,989

4,023

4,068

0

0

0

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

Merger transaction costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Restructuring expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Loss on impairment of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Total costs and expenses

5,373

5,814

6,063

6,478

7,126

8,118

10,888

13,701

17,104

18,712

18,707

18,944

17,326

16,613

15,496

13,601

12,379

11,455

10,565

0

0

-

0

-

-

0

0

0

0

0

0

0

Total costs and expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

Loss from operations

-5,373

-5,814

-6,063

-6,478

-7,126

-8,118

-10,888

-13,701

-17,104

-18,712

-18,707

-18,944

-17,326

-16,613

-15,496

-13,601

-12,379

-11,455

-10,892

-10,360

-10,047

-9,693

-8,806

-7,719

0

0

0

0

0

0

0

0

Gain on assignment of patent rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Gain on bargain purchase

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Interest and other income

158

172

174

164

159

162

163

167

163

167

176

185

193

169

128

79

34

14

8

6

6

7

8

7

0

0

0

0

0

0

0

-

Interest expense

8

7

7

8

8

8

8

8

7

6

0

0

0

-

-

-

-

4

4

4

3

3

0

0

0

-

-

-

-

-

-

-

Loss before income taxes

-5,223

-5,649

-5,896

-6,322

-6,975

-7,964

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Interest and other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

Income tax benefit

-

-167

-182

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

Net loss

-5,138

-5,482

-5,745

-6,182

-6,862

-7,933

-10,641

-13,481

-16,887

-18,490

-18,537

-18,763

-17,135

-16,444

-15,368

-13,523

-12,348

-11,445

-10,888

-10,358

-10,044

-9,689

-8,801

-7,716

0

0

0

0

0

0

0

0

Change in unrealized loss on marketable securities

-

-

-

-

-

2

3

5

9

17

3

-18

-15

-19

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-5,745

-6,182

-

-7,931

-10,638

-13,476

-16,878

-18,473

-18,534

-18,781

-17,150

-16,463

-15,374

-13,510

-12,342

-11,445

0

0

0

-

-

-

-

-

-

-

-

-

-

-

Net loss per share:
Less: Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

Less: Deemed preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Net loss available to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

Basic and diluted

-0.83

-0.39

-0.76

-1.14

-1.86

-1.90

-2.06

-2.74

-3.61

-0.31

-0.39

-0.59

-0.48

-0.47

-0.51

-0.43

-0.40

0.09

-0.31

-0.69

-0.91

-2.31

-0.76

-0.11

-0.13

-0.16

-0.65

-0.07

-

-0.17

-

-

Weighted average shares outstanding:
Basic and diluted

1,594

1,603

1,521

1,263

895

773

773

773

756

11,803

11,502

9,324

9,094

9,082

9,068

9,065

9,053

9,147

9,034

3,951

3,023

-31,084

3,004

21,009

18,785

10,832

4,944

13,702

-

10,499

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.09

-

0.03

-0.26

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.09

-

0.03

-0.26

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,166

-

10,129

8,732

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,166

-

10,250

8,732